Liyi Zou1, Shaoru Chen2, Li Li3, Tie Wu4. 1. School of Pharmacy, Guangdong Medical University, Dongguan 523-808, China. 2. State key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China. 3. Dongguan Scientific Research Center, Guangong Medical University, Dongguan, Guangdong, 523-808, China. Electronic address: china_lovelylily@hotmail.com. 4. School of Pharmacy, Guangdong Medical University, Dongguan 523-808, China. Electronic address: Wutie2@163.com.
Abstract
CONTEXT: Hyperoside was used to treat cardiovascular disease for many years in China. It was shown great effect on regulation of lipid metabolism. But there is lack of reports about the effects of hyperoside on liver diseases. OBJECTIVE: This study was designed to investigate the potentially protective effects of hyperoside and the role of transcription factor nuclear factor-erythroid 2(NF-E2)-related factor 2 (Nrf2) signaling in the regulation on Carbon Tetrachloride (CCl4)-induced chronic liver fibrosis in mice. MATERIALS AND METHODS: All mice were divided into six groups containing 6 animals per group. Mice in different group were given relative processing for 4 weeks. The potentially protective effects of hyperoside on CCl4-induced chronic liver fibrosis in mice were depicted histologically and biochemically. RESULTS: CCl4 administration caused a marked increase in the levels of serum aminotransferases, serum monoamine oxidase (MAO) and lipid peroxidation, MAO in mouse liver homogenates. Also decreased activities of cellular antioxidant defense enzymes were found after CCl4 exposure. Histopathological changes induced by CCl4 including regenerative nodules, deteriorated parenchyma. Hyperoside and silymarin reduced these changes and attenuated the pathological effects of CCl4 induced liver injury. In addition, hyperoside exhibited antioxidant effects in vitro. In Western blot analysis, the protein level of Nrf2 was downregulated after CCl4 administration and reversed by hyperoside. CONCLUSION: Hyperoside increased the activity of the antioxidant and phase II detoxifying enzymes through the activation of Nrf2 nuclear translocated in the CCl4-induced liver fibrosis mice.
CONTEXT: Hyperoside was used to treat cardiovascular disease for many years in China. It was shown great effect on regulation of lipid metabolism. But there is lack of reports about the effects of hyperoside on liver diseases. OBJECTIVE: This study was designed to investigate the potentially protective effects of hyperoside and the role of transcription factor nuclear factor-erythroid 2(NF-E2)-related factor 2 (Nrf2) signaling in the regulation on Carbon Tetrachloride (CCl4)-induced chronic liver fibrosis in mice. MATERIALS AND METHODS: All mice were divided into six groups containing 6 animals per group. Mice in different group were given relative processing for 4 weeks. The potentially protective effects of hyperoside on CCl4-induced chronic liver fibrosis in mice were depicted histologically and biochemically. RESULTS:CCl4 administration caused a marked increase in the levels of serum aminotransferases, serum monoamine oxidase (MAO) and lipid peroxidation, MAO in mouse liver homogenates. Also decreased activities of cellular antioxidant defense enzymes were found after CCl4 exposure. Histopathological changes induced by CCl4 including regenerative nodules, deteriorated parenchyma. Hyperoside and silymarin reduced these changes and attenuated the pathological effects of CCl4 induced liver injury. In addition, hyperoside exhibited antioxidant effects in vitro. In Western blot analysis, the protein level of Nrf2 was downregulated after CCl4 administration and reversed by hyperoside. CONCLUSION:Hyperoside increased the activity of the antioxidant and phase II detoxifying enzymes through the activation of Nrf2 nuclear translocated in the CCl4-induced liver fibrosismice.
Authors: Daniel Rodrigo Cavalcante de Araújo; Túlio Diego da Silva; Wolfgang Harand; Claudia Sampaio de Andrade Lima; João Paulo Ferreira Neto; Bárbara de Azevedo Ramos; Tamiris Alves Rocha; Harley da Silva Alves; Rayane Sobrinho de Sousa; Ana Paula de Oliveira; Luís Cláudio Nascimento da Silva; Jackson Roberto Guedes da Silva Almeida; Márcia Vanusa da Silva; Maria Tereza Dos Santos Correia Journal: Biomolecules Date: 2019-10-08
Authors: Bruna Maria Pereira da Costa Cordeiro; Nataly Diniz de Lima Santos; Magda Rhayanny Assunção Ferreira; Larissa Cardoso Corrêa de Araújo; Alexsander Rodrigues Carvalho Junior; Alan Diego da Conceição Santos; Ana Paula de Oliveira; Alexandre Gomes da Silva; Emerson Peter da Silva Falcão; Maria Tereza Dos Santos Correia; Jackson Roberto Guedes da Silva Almeida; Luís Cláudio Nascimento da Silva; Luiz Alberto Lira Soares; Thiago Henrique Napoleão; Márcia Vanusa da Silva; Patrícia Maria Guedes Paiva Journal: BMC Complement Altern Med Date: 2018-10-19 Impact factor: 3.659
Authors: Jizhen Huang; Xiang Tong; Li Zhang; Yuan Zhang; Lei Wang; Dongguang Wang; Shijie Zhang; Hong Fan Journal: Front Pharmacol Date: 2020-10-22 Impact factor: 5.810